Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

Journal of the Neurological Sciences

Volumn 328, Issue 1-2, 2013, Pages 9-18

  Groves, Aran ^a   Kihara, Yasuyuki ^a   Chun, Jerold ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Experimental autoimmune encephalitis; Fingolimod; Lysophospholipids; Multiple sclerosis; Neuroprotection; S1P; Sphingosine 1 phosphate receptor modulator

Indexed keywords

BETA INTERFERON; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FINGOLIMOD; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NATALIZUMAB; PROTEIN KINASE B; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ARTICLE; ASTROCYTE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; BRAIN SIZE; CYTOKINE PRODUCTION; DEMYELINATION; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; EXCITATORY POSTSYNAPTIC POTENTIAL; HUMAN; LYMPHOCYTE MIGRATION; MICROGLIA; MULTIPLE SCLEROSIS; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMYELINIZATION; SIGNAL TRANSDUCTION; SYNAPSE; TREATMENT RESPONSE; WHITE MATTER;

EID: 84876119766     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.02.011     Document Type: Review

References (189)

1. G.M. Strub, M. Maceyka, N.C. Hait, S. Milstien, and S. Spiegel Extracellular and intracellular actions of sphingosine-1-phosphate Adv Exp Med Biol 688 2010 141 155
2. M. Maceyka, K.B. Harikumar, S. Milstien, and S. Spiegel Sphingosine-1-phosphate signaling and its role in disease Trends Cell Biol 22 2012 50 60
3. T. Mutoh, R. Rivera, and J. Chun Insights into the pharmacological relevance of lysophospholipid receptors Br J Pharmacol 165 2012 829 844
4. J.N. Kanfer, O.M. Young, D. Shapiro, and R.O. Brady The metabolism of sphingomyelin. I. Purification and properties of a sphingomyelin-cleaving enzyme from rat liver tissue J Biol Chem 241 1966 1081 1084
5. M. Tani, M. Ito, and Y. Igarashi Ceramide/sphingosine/sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space Cell Signal 19 2007 229 237 (Pubitemid 44969975)
6. T. Kohama, A. Olivera, L. Edsall, M.M. Nagiec, R. Dickson, and S. Spiegel Molecular cloning and functional characterization of murine sphingosine kinase J Biol Chem 273 1998 23722 23728 (Pubitemid 28435703)
7. H. Liu, M. Sugiura, V.E. Nava, L.C. Edsall, K. Kono, and S. Poulton Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform J Biol Chem 275 2000 19513 19520 (Pubitemid 30441543)
8. J. Chun, and H.P. Hartung Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin Neuropharmacol 33 2010 91 101
9. K. Noguchi, and J. Chun Roles for lysophospholipid S1P receptors in multiple sclerosis Crit Rev Biochem Mol Biol 46 2011 2 10
10. J.H. Hecht, J.A. Weiner, S.R. Post, and J. Chun Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex J Cell Biol 135 1996 1071 1083 (Pubitemid 26403779)
11. S. An, T. Bleu, W. Huang, O.G. Hallmark, S.R. Coughlin, and E.J. Goetzl Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids FEBS Lett 417 1997 279 282 (Pubitemid 27511604)
12. S. An, T. Bleu, O.G. Hallmark, and E.J. Goetzl Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid J Biol Chem 273 1998 7906 7910 (Pubitemid 28168837)
13. M.J. Lee, J.R. Van Brocklyn, S. Thangada, C.H. Liu, A.R. Hand, and R. Menzeleev Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1 Science 279 1998 1552 1555 (Pubitemid 28217081)
14. M.J. Lee, S. Thangada, C.H. Liu, B.D. Thompson, and T. Hla Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist J Biol Chem 273 1998 22105 22112 (Pubitemid 28405394)
15. G. Zhang, J.J. Contos, J.A. Weiner, N. Fukushima, and J. Chun Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate Gene 227 1999 89 99 (Pubitemid 29071235)
16. J.A. Weiner, J.H. Hecht, and J. Chun Lysophosphatidic acid receptor gene vzg-1/lpA1/edg-2 is expressed by mature oligodendrocytes during myelination in the postnatal murine brain J Comp Neurol 398 1998 587 598 (Pubitemid 28364536)
17. A.E. Dubin, T. Bahnson, J.A. Weiner, N. Fukushima, and J. Chun Lysophosphatidic acid stimulates neurotransmitter-like conductance changes that precede GABA and l-glutamate in early, presumptive cortical neuroblasts J Neurosci 19 1999 1371 1381 (Pubitemid 29088919)
18. J.A. Weiner, and J. Chun Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid Proc Natl Acad Sci U S A 96 1999 5233 5238 (Pubitemid 29214566)
19. J.J. Contos, N. Fukushima, J.A. Weiner, D. Kaushal, and J. Chun Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior Proc Natl Acad Sci U S A 97 2000 13384 13389
20. N. Fukushima, J.A. Weiner, and J. Chun Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology Dev Biol 228 2000 6 18
21. I. Ishii, J.J. Contos, N. Fukushima, and J. Chun Functional comparisons of the lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system Mol Pharmacol 58 2000 895 902
22. I. Ishii, B. Friedman, X. Ye, S. Kawamura, C. McGiffert, and J.J. Contos Selective loss of sphingosine 1-phosphate signaling with no obvious phenotypic abnormality in mice lacking its G protein-coupled receptor, LP(B3)/EDG-3 J Biol Chem 276 2001 33697 33704
23. J.A. Weiner, N. Fukushima, J.J. Contos, S.S. Scherer, and J. Chun Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling J Neurosci 21 2001 7069 7078 (Pubitemid 32846954)
24. J.J. Contos, I. Ishii, N. Fukushima, M.A. Kingsbury, X. Ye, and S. Kawamura Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2) Mol Cell Biol 22 2002 6921 6929
25. N. Fukushima, I. Ishii, Y. Habara, C.B. Allen, and J. Chun Dual regulation of actin rearrangement through lysophosphatidic acid receptor in neuroblast cell lines: actin depolymerization by Ca(2 +)-alpha-actinin and polymerization by rho Mol Biol Cell 13 2002 2692 2705
26. N. Fukushima, J.A. Weiner, D. Kaushal, J.J. Contos, S.K. Rehen, and M.A. Kingsbury Lysophosphatidic acid influences the morphology and motility of young, postmitotic cortical neurons Mol Cell Neurosci 20 2002 271 282 (Pubitemid 34762136)
27. C. McGiffert, J.J. Contos, B. Friedman, and J. Chun Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis FEBS Lett 531 2002 103 108 (Pubitemid 35232794)
28. M.A. Kingsbury, S.K. Rehen, J.J. Contos, C.M. Higgins, and J. Chun Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding Nat Neurosci 6 2003 1292 1299 (Pubitemid 37485123)
29. T.S. Rao, K.D. Lariosa-Willingham, F.F. Lin, E.L. Palfreyman, N. Yu, and J. Chun Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes Brain Res 990 2003 182 194 (Pubitemid 37244074)
30. M. Inoue, M.H. Rashid, R. Fujita, J.J. Contos, J. Chun, and H. Ueda Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling Nat Med 10 2004 712 718 (Pubitemid 38937636)
31. T.S. Rao, K.D. Lariosa-Willingham, F.F. Lin, N. Yu, C.S. Tham, and J. Chun Growth factor pre-treatment differentially regulates phosphoinositide turnover downstream of lysophospholipid receptor and metabotropic glutamate receptors in cultured rat cerebrocortical astrocytes Int J Dev Neurosci 22 2004 131 135 (Pubitemid 38597128)
32. M. Webb, C.S. Tham, F.F. Lin, K. Lariosa-Willingham, N. Yu, and J. Hale Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice J Neuroimmunol 153 2004 108 121 (Pubitemid 38950933)
33. N. Fukushima, S. Shano, R. Moriyama, and J. Chun Lysophosphatidic acid stimulates neuronal differentiation of cortical neuroblasts through the LPA1-G(i/o) pathway Neurochem Int 50 2007 302 307 (Pubitemid 46097172)
34. D.R. Herr, N. Grillet, M. Schwander, R. Rivera, U. Muller, and J. Chun Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2 J Neurosci 27 2007 1474 1478
35. G. Estivill-Torrus, P. Llebrez-Zayas, E. Matas-Rico, L. Santin, C. Pedraza, and I. De Diego Absence of LPA1 signaling results in defective cortical development Cereb Cortex 18 2008 938 950 (Pubitemid 351398359)
36. J.W. Choi, and J. Chun Lysophospholipids and their receptors in the central nervous system Biochim Biophys Acta 2013 1831 20 32
37. M.E. Lin, R.R. Rivera, and J. Chun Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain J Biol Chem 287 2012 17608 17617
38. K.J. Herr, D.R. Herr, C.W. Lee, K. Noguchi, and J. Chun Stereotyped fetal brain disorganization is induced by hypoxia and requires lysophosphatidic acid receptor 1 (LPA1) signaling Proc Natl Acad Sci U S A 108 2011 15444 15449
39. Y.C. Yung, T. Mutoh, M.E. Lin, K. Noguchi, R.R. Rivera, and J.W. Choi Lysophosphatidic acid signaling may initiate fetal hydrocephalus Sci Transl Med 3 2011 99ra87
40. S.P. Welch, L.J. Sim-Selley, and D.E. Selley Sphingosine-1-phosphate receptors as emerging targets for treatment of pain Biochem Pharmacol 84 2012 1551 1562
41. J. Liu, C. Zhang, W. Tao, and M. Liu Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke Int J Neurosci 123 2013 163 169
42. Y. Norimatsu, T. Ohmori, A. Kimura, S. Madoiwa, J. Mimuro, and A. Seichi FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms Am J Pathol 180 2012 1625 1635
43. C.S. Tham, F.F. Lin, T.S. Rao, N. Yu, and M. Webb Microglial activation state and lysophospholipid acid receptor expression Int J Dev Neurosci 21 2003 431 443 (Pubitemid 37491477)
44. B. Soliven, V. Miron, and J. Chun The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators Neurology 76 2011 S9 S14
45. N. Fukushima, I. Ishii, J.J. Contos, J.A. Weiner, and J. Chun Lysophospholipid receptors Annu Rev Pharmacol Toxicol 41 2001 507 534 (Pubitemid 32385897)
46. S. Siehler, and D.R. Manning Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors Biochim Biophys Acta 1582 2002 94 99 (Pubitemid 34634116)
47. B. Anliker, and J. Chun Lysophospholipid G protein-coupled receptors J Biol Chem 279 2004 20555 20558 (Pubitemid 38656446)
48. I. Ishii, N. Fukushima, X. Ye, and J. Chun Lysophospholipid receptors: signaling and biology Annu Rev Biochem 73 2004 321 354 (Pubitemid 39050372)
49. A.S. Novgorodov, M. El-Alwani, J. Bielawski, L.M. Obeid, and T.I. Gudz Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration FASEB J 21 2007 1503 1514 (Pubitemid 46684852)
50. S. Mandala, R. Hajdu, J. Bergstrom, E. Quackenbush, J. Xie, and J. Milligan Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists Science 296 2002 346 349 (Pubitemid 34303689)
51. V. Brinkmann, M.D. Davis, C.E. Heise, R. Albert, S. Cottens, and R. Hof The immune modulator FTY720 targets sphingosine 1-phosphate receptors J Biol Chem 277 2002 21453 21457 (Pubitemid 34952287)
52. V. Brinkmann, A. Billich, T. Baumruker, P. Heining, R. Schmouder, and G. Francis Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat Rev Drug Discov 9 2010 883 897
53. J. Chun, and V. Brinkmann A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya) Discov Med 12 2011 213 228
54. J.A. Cohen, and J. Chun Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis Ann Neurol 69 2011 759 777
55. M. Matloubian, C.G. Lo, G. Cinamon, M.J. Lesneski, Y. Xu, and V. Brinkmann Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 Nature 427 2004 355 360 (Pubitemid 38133663)
56. M.H. Graler, and E.J. Goetzl The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors FASEB J 18 2004 551 553
57. M.L. Oo, S. Thangada, M.T. Wu, C.H. Liu, T.L. Macdonald, and K.R. Lynch Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor J Biol Chem 282 2007 9082 9089 (Pubitemid 47093504)
58. M. Graeler, and E.J. Goetzl Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells FASEB J 16 2002 1874 1878 (Pubitemid 35462606)
59. M. Mehling, V. Brinkmann, J. Antel, A. Bar-Or, N. Goebels, and C. Vedrine FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis Neurology 71 2008 1261 1267
60. R. Pappu, S.R. Schwab, I. Cornelissen, J.P. Pereira, J.B. Regard, and Y. Xu Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate Science 316 2007 295 298 (Pubitemid 46633109)
61. C.A. Foster, L.M. Howard, A. Schweitzer, E. Persohn, P.C. Hiestand, and B. Balatoni Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis J Pharmacol Exp Ther 323 2007 469 475
62. V.E. Miron, A. Schubart, and J.P. Antel Central nervous system-directed effects of FTY720 (fingolimod) J Neurol Sci 274 2008 13 17
63. V.E. Miron, S.K. Ludwin, P.J. Darlington, A.A. Jarjour, B. Soliven, and T.E. Kennedy Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices Am J Pathol 176 2010 2682 2694
64. J.W. Choi, S.E. Gardell, D.R. Herr, R. Rivera, C.W. Lee, and K. Noguchi FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation Proc Natl Acad Sci U S A 108 2011 751 756
65. D. Wheeler, V.V. Bandaru, P.A. Calabresi, A. Nath, and N.J. Haughey A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis Brain 131 2008 3092 3102
66. A. Kulakowska, M. Zendzian-Piotrowska, M. Baranowski, T. Kononczuk, W. Drozdowski, and J. Gorski Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis Neurosci Lett 477 2010 149 152
67. J. Qin, E. Berdyshev, J. Goya, V. Natarajan, and G. Dawson Neurons and oligodendrocytes recycle sphingosine 1-phosphate to ceramide: significance for apoptosis and multiple sclerosis J Biol Chem 285 2010 14134 14143
68. R. Van Doorn, J. Van Horssen, D. Verzijl, M. Witte, E. Ronken, and B. Van Het Hof Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions Glia 58 2010 1465 1476
69. I. Fischer, C. Alliod, N. Martinier, J. Newcombe, C. Brana, and S. Pouly Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions PLoS One 6 2011 e23905
70. N. Stahl, and G.D. Yancopoulos The tripartite CNTF receptor complex: activation and signaling involves components shared with other cytokines J Neurobiol 25 1994 1454 1466 (Pubitemid 24325068)
71. A. Bonni, Y. Sun, M. Nadal-Vicens, A. Bhatt, D.A. Frank, and I. Rozovsky Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway Science 278 1997 477 483 (Pubitemid 27454434)
72. M. Murphy, R. Dutton, S. Koblar, S. Cheema, and P. Bartlett Cytokines which signal through the LIF receptor and their actions in the nervous system Prog Neurobiol 52 1997 355 378 (Pubitemid 27376651)
73. F. Barnabe-Heider, J.A. Wasylnka, K.J. Fernandes, C. Porsche, M. Sendtner, and D.R. Kaplan Evidence that embryonic neurons regulate the onset of cortical gliogenesis via cardiotrophin-1 Neuron 48 2005 253 265 (Pubitemid 41476359)
74. D.D. Wang, and A. Bordey The astrocyte odyssey Prog Neurobiol 86 2008 342 367
75. F.W. Pfrieger Roles of glial cells in synapse development Cell Mol Life Sci 66 2009 2037 2047
76. M.V. Sofroniew, and H.V. Vinters Astrocytes: biology and pathology Acta Neuropathol 119 2010 7 35
77. I. Allaman, M. Belanger, and P.J. Magistretti Astrocyte-neuron metabolic relationships: for better and for worse Trends Neurosci 34 2011 76 87
78. A.V. Molofsky, R. Krencik, E.M. Ullian, H.H. Tsai, B. Deneen, and W.D. Richardson Astrocytes and disease: a neurodevelopmental perspective Genes Dev 26 2012 891 907
79. D. Miljkovic, G. Timotijevic, and M. Mostarica Stojkovic Astrocytes in the tempest of multiple sclerosis FEBS Lett 585 2011 3781 3788
80. C.S. Moore, S.L. Abdullah, A. Brown, A. Arulpragasam, and S.J. Crocker How factors secreted from astrocytes impact myelin repair J Neurosci Res 89 2011 13 21
81. J. Luo, P. Ho, L. Steinman, and T. Wyss-Coray Bioluminescence in vivo imaging of autoimmune encephalomyelitis predicts disease J Neuroinflammation 5 2008 6
82. A. Pebay, M. Toutant, J. Premont, C.F. Calvo, L. Venance, and J. Cordier Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades Eur J Neurosci 13 2001 2067 2076 (Pubitemid 32664301)
83. V. Anelli, R. Bassi, G. Tettamanti, P. Viani, and L. Riboni Extracellular release of newly synthesized sphingosine-1-phosphate by cerebellar granule cells and astrocytes J Neurochem 92 2005 1204 1215 (Pubitemid 40344310)
84. S.D. Sorensen, O. Nicole, R.D. Peavy, L.M. Montoya, C.J. Lee, and T.J. Murphy Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes Mol Pharmacol 64 2003 1199 1209 (Pubitemid 37310753)
85. Y.P. Wu, K. Mizugishi, M. Bektas, R. Sandhoff, and R.L. Proia Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease Hum Mol Genet 17 2008 2257 2264
86. F. Mullershausen, L.M. Craveiro, Y. Shin, M. Cortes-Cros, F. Bassilana, and M. Osinde Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors J Neurochem 102 2007 1151 1161 (Pubitemid 47174238)
87. M. Osinde, F. Mullershausen, and K.K. Dev Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors Neuropharmacology 52 2007 1210 1218 (Pubitemid 46546406)
88. R.H. Miller, and S. Mi Dissecting demyelination Nat Neurosci 10 2007 1351 1354 (Pubitemid 350014684)
89. K. Terai, T. Soga, M. Takahashi, M. Kamohara, K. Ohno, and S. Yatsugi Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS Neuroscience 116 2003 1053 1062 (Pubitemid 36262963)
90. N. Yu, K.D. Lariosa-Willingham, F.F. Lin, M. Webb, and T.S. Rao Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes Glia 45 2004 17 27 (Pubitemid 38076224)
91. C. Jaillard, S. Harrison, B. Stankoff, M.S. Aigrot, A.R. Calver, and G. Duddy Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival J Neurosci 25 2005 1459 1469 (Pubitemid 40250722)
92. C.G. Jung, H.J. Kim, V.E. Miron, S. Cook, T.E. Kennedy, and C.A. Foster Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells Glia 55 2007 1656 1667 (Pubitemid 47612852)
93. V.E. Miron, J.A. Hall, T.E. Kennedy, B. Soliven, and J.P. Antel Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod Am J Pathol 173 2008 1143 1152
94. V.E. Miron, C.G. Jung, H.J. Kim, T.E. Kennedy, B. Soliven, and J.P. Antel FTY720 modulates human oligodendrocyte progenitor process extension and survival Ann Neurol 63 2008 61 71 (Pubitemid 351240552)
95. R.P. Coelho, S.G. Payne, R. Bittman, S. Spiegel, and C. Sato-Bigbee The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors J Pharmacol Exp Ther 323 2007 626 635 (Pubitemid 350005137)
96. J. Harada, M. Foley, M.A. Moskowitz, and C. Waeber Sphingosine-1- phosphate induces proliferation and morphological changes of neural progenitor cells J Neurochem 88 2004 1026 1039 (Pubitemid 38199325)
97. T. Kajimoto, T. Okada, H. Yu, S.K. Goparaju, S. Jahangeer, and S. Nakamura Involvement of sphingosine-1-phosphate in glutamate secretion in hippocampal neurons Mol Cell Biol 27 2007 3429 3440 (Pubitemid 46685218)
98. K. Mizugishi, T. Yamashita, A. Olivera, G.F. Miller, S. Spiegel, and R.L. Proia Essential role for sphingosine kinases in neural and vascular development Mol Cell Biol 25 2005 11113 11121 (Pubitemid 41747151)
99. A.J. MacLennan, P.R. Carney, W.J. Zhu, A.H. Chaves, J. Garcia, and J.R. Grimes An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability Eur J Neurosci 14 2001 203 209 (Pubitemid 32777628)
100. M. Kono, I.A. Belyantseva, A. Skoura, G.I. Frolenkov, M.F. Starost, and J.L. Dreier Deafness and stria vascularis defects in S1P2 receptor-null mice J Biol Chem 282 2007 10690 10696 (Pubitemid 47093459)
101. I. Ishii, X. Ye, B. Friedman, S. Kawamura, J.J. Contos, and M.A. Kingsbury Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3 J Biol Chem 277 2002 25152 25159 (Pubitemid 34951821)
102. N. Akahoshi, Y. Ishizaki, H. Yasuda, Y.L. Murashima, T. Shinba, and K. Goto Frequent spontaneous seizures followed by spatial working memory/anxiety deficits in mice lacking sphingosine 1-phosphate receptor 2 Epilepsy Behav 22 2011 659 665
103. L.C. Edsall, G.G. Pirianov, and S. Spiegel Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation J Neurosci 17 1997 6952 6960 (Pubitemid 27427874)
104. R.E. Toman, S.G. Payne, K.R. Watterson, M. Maceyka, N.H. Lee, and S. Milstien Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension J Cell Biol 166 2004 381 392 (Pubitemid 39031241)
105. Y.H. Zhang, M.R. Vasko, and G.D. Nicol Intracellular sphingosine 1-phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons J Physiol 575 2006 101 113 (Pubitemid 44178131)
106. L. Di Menna, G. Molinaro, L. Di Nuzzo, B. Riozzi, C. Zappulla, and C. Pozzilli Fingolimod protects cultured cortical neurons against excitotoxic death Pharmacol Res 67 2013 1 9
107. C.R. Rau, K. Hein, M.B. Sattler, B. Kretzschmar, C. Hillgruber, and B.L. McRae Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis Am J Pathol 178 2011 1770 1781
108. S. Rossi, T. Lo Giudice, V. De Chiara, A. Musella, V. Studer, and C. Motta Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis Br J Pharmacol 165 2012 861 869
109. Z. Gao, and S.E. Tsirka Animal models of MS reveal multiple roles of microglia in disease pathogenesis Neurol Res Int 2011 2011 383087
110. R.A. Adams, J. Bauer, M.J. Flick, S.L. Sikorski, T. Nuriel, and H. Lassmann The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease J Exp Med 204 2007 571 582 (Pubitemid 46457080)
111. D. Nayak, Y. Huo, W.X. Kwang, P.N. Pushparaj, S.D. Kumar, and E.A. Ling Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia Neuroscience 166 2010 132 144
112. B.A. Durafourt, C. Lambert, T.A. Johnson, M. Blain, A. Bar-Or, and J.P. Antel Differential responses of human microglia and blood-derived myeloid cells to FTY720 J Neuroimmunol 230 2011 10 16
113. T. Yoshino, H. Tabunoki, S. Sugiyama, K. Ishii, S.U. Kim, and J. Satoh Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2 Cell Mol Neurobiol 31 2011 1009 1020
114. Z. Zhang, Z. Zhang, U. Fauser, M. Artelt, M. Burnet, and H.J. Schluesener FTY720 attenuates accumulation of EMAP-II+ and MHC-II+ monocytes in early lesions of rat traumatic brain injury J Cell Mol Med 11 2007 307 314 (Pubitemid 46693329)
115. B. Czech, W. Pfeilschifter, N. Mazaheri-Omrani, M.A. Strobel, T. Kahles, and T. Neumann-Haefelin The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia Biochem Biophys Res Commun 389 2009 251 256
116. S.J. Jackson, G. Giovannoni, and D. Baker Fingolimod modulates microglial activation to augment markers of remyelination J Neuroinflammation 8 2011 76
117. M. Comabella, X. Montalban, C. Munz, and J.D. Lunemann Targeting dendritic cells to treat multiple sclerosis Nat Rev Neurol 6 2010 499 507
118. A.L. Zozulya, B.D. Clarkson, S. Ortler, Z. Fabry, and H. Wiendl The role of dendritic cells in CNS autoimmunity J Mol Med (Berl) 88 2010 535 544
119. G. Galicia-Rosas, N. Pikor, J.A. Schwartz, O. Rojas, A. Jian, and L. Summers-Deluca A sphingosine-1-phosphate receptor 1-directed agonist reduces central nervous system inflammation in a plasmacytoid dendritic cell-dependent manner J Immunol 189 2012 3700 3706
120. M. Stasiolek, A. Bayas, N. Kruse, A. Wieczarkowiecz, K.V. Toyka, and R. Gold Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis Brain 129 2006 1293 1305
121. Y.Y. Lan, A. De Creus, B.L. Colvin, M. Abe, V. Brinkmann, and P.T. Coates The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo Am J Transplant 5 2005 2649 2659
122. Y. Gao, B. Majchrzak-Kita, E.N. Fish, and J.L. Gommerman Dynamic accumulation of plasmacytoid dendritic cells in lymph nodes is regulated by interferon-beta Blood 114 2009 2623 2631
123. J. Correale, and A. Villa The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting Autoimmunity 40 2007 148 160
124. M.J. Lee, S. Thangada, K.P. Claffey, N. Ancellin, C.H. Liu, and M. Kluk Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate Cell 99 1999 301 312 (Pubitemid 29519909)
125. D. Zhu, Y. Wang, I. Singh, R.D. Bell, R. Deane, and Z. Zhong Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor Blood 115 2010 4963 4972
126. T. Sanchez, T. Estrada-Hernandez, J.H. Paik, M.T. Wu, K. Venkataraman, and V. Brinkmann Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability J Biol Chem 278 2003 47281 47290 (Pubitemid 37452317)
127. X. Peng, P.M. Hassoun, S. Sammani, B.J. McVerry, M.J. Burne, and H. Rabb Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury Am J Respir Crit Care Med 169 2004 1245 1251 (Pubitemid 38680403)
128. S.M. Dudek, S.M. Camp, E.T. Chiang, P.A. Singleton, P.V. Usatyuk, and Y. Zhao Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor Cell Signal 19 2007 1754 1764 (Pubitemid 46935431)
129. J. Correale, and A. Villa Cellular elements of the blood-brain barrier Neurochem Res 34 2009 2067 2077
130. M.L. Cuzner, and G. Opdenakker Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system J Neuroimmunol 94 1999 1 14 (Pubitemid 29071238)
131. E. Waubant, D.E. Goodkin, L. Gee, P. Bacchetti, R. Sloan, and T. Stewart Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis Neurology 53 1999 1397 1401 (Pubitemid 29491927)
132. C.A. Foster, D. Mechtcheriakova, M.K. Storch, B. Balatoni, L.M. Howard, and F. Bornancin FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage Brain Pathol 19 2009 254 266
133. S. Al-Izki, G. Pryce, S.J. Jackson, G. Giovannoni, and D. Baker Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis Mult Scler 17 2011 939 948
134. B. Balatoni, M.K. Storch, E.M. Swoboda, V. Schonborn, A. Koziel, and G.N. Lambrou FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis Brain Res Bull 74 2007 307 316 (Pubitemid 47368881)
135. H. Kataoka, K. Sugahara, K. Shimano, K. Teshima, M. Koyama, and A. Fukunari FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration Cell Mol Immunol 2 2005 439 448
136. D. Papadopoulos, J. Rundle, R. Patel, I. Marshall, J. Stretton, and R. Eaton FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses J Neurosci Res 88 2010 346 359
137. Y. Hu, X. Lee, B. Ji, K. Guckian, D. Apicco, and R.B. Pepinsky Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo Mol Cell Neurosci 48 2011 72 81
138. H.J. Kim, V.E. Miron, D. Dukala, R.L. Proia, S.K. Ludwin, and M. Traka Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model FASEB J 25 2011 1509 1518
139. D.C. Anthony, N.R. Sibson, P. Losey, D. Piani Meier, and D. Leppert Oral fingolimod (FTY720) therapy reduces blood-brain barrier breakdown, microglial activation, and leukocyte recruitment in a focal DTH model of multiple sclerosis Mult Scler 15 2009 S275
140. D.C. Anthony, N.R. Sibson, D. Leppert, and Meier D. Piani Fingolimod (FTY720) therapy reduces demyelination and microglial activation in a focal DTH model of multiple sclerosis during the remission phase Mult Scler 16 2010 S283
141. R. Deogracias, M. Yazdani, M.P. Dekkers, J. Guy, M.C. Ionescu, and K.E. Vogt Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome Proc Natl Acad Sci U S A 109 2012 14230 14235
142. G.K. Sheridan, and K.K. Dev S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures Glia 60 2012 382 392
143. M. Kipp, and S. Amor FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination Mult Scler 18 2012 258 263
144. US Food and Drug Administration Gilenya prescribing information 2010
145. European Medicines Agency Annex I. Summary of product characteristics. Gilenya (fingolimod) 2011
146. J.A. Cohen, F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, and X. Montalban Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
147. L. Kappos, E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, and P. Calabresi A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
148. A. Shirani, Y. Zhao, M.E. Karim, C. Evans, E. Kingwell, and M.L. van der Kop Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis JAMA 308 2012 247 256
149. F. Barkhof, P.A. Calabresi, D.H. Miller, and S.C. Reingold Imaging outcomes for neuroprotection and repair in multiple sclerosis trials Nat Rev Neurol 5 2009 256 266
150. R.A. Bermel, and R. Bakshi The measurement and clinical relevance of brain atrophy in multiple sclerosis Lancet Neurol 5 2006 158 170 (Pubitemid 43107851)
151. J.H. Simon Brain atrophy in multiple sclerosis: what we know and would like to know Mult Scler 12 2006 679 687 (Pubitemid 46111759)
152. E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, and K. Selmaj Impact of fingolimod therapy on MRI outcomes in patients with multiple sclerosis Arch Neurol 69 2012 1259 1269
153. R. Zivadinov, A.T. Reder, M. Filippi, A. Minagar, O. Stuve, and H. Lassmann Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis Neurology 71 2008 136 144
154. D.H. Miller, and S.M. Leary Primary-progressive multiple sclerosis Lancet Neurol 6 2007 903 912 (Pubitemid 47405002)
155. ClinicalTrials.gov FTY720 in patients with primary progressive multiple sclerosis (INFORMS) 2011 [Updated November 16, 2011]
156. H.J. Kim, C.G. Jung, D. Dukala, H. Bae, R. Kakazu, and R. Wollmann Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy J Neuroimmunol 214 2009 93 100
157. Z. Zhang, Z.Y. Zhang, U. Fauser, and H.J. Schluesener FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves Exp Neurol 210 2008 681 690
158. A.G. Commodaro, J.P. Peron, C.T. Lopes, C. Arslanian, R. Belfort Jr., and L.V. Rizzo Evaluation of experimental autoimmune uveitis in mice treated with FTY720 Invest Ophthalmol Vis Sci 51 2010 2568 2574
159. T. Maki, R. Gottschalk, N. Ogawa, and A.P. Monaco Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720 Transplantation 79 2005 1051 1055 (Pubitemid 40663996)
160. J. Popovic, K.L. Kover, and W.V. Moore The effect of immunomodulators on prevention of autoimmune diabetes is stage dependent: FTY720 prevents diabetes at three different stages in the diabetes-resistant biobreeding rat Pediatr Diabetes 5 2004 3 9 (Pubitemid 38489438)
161. K. Huang, S.Q. Li, W.J. Wang, L.S. Liu, Y.G. Jiang, and P.N. Feng Oral FTY720 administration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice Int J Immunopathol Pharmacol 25 2012 397 406
162. M. Kitano, T. Hla, M. Sekiguchi, Y. Kawahito, R. Yoshimura, and K. Miyazawa Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression Arthritis Rheum 54 2006 742 753
163. H. Takeshita, M. Kitano, T. Iwasaki, S. Kitano, S. Tsunemi, and C. Sato Sphingosine 1-phosphate (S1P)/S1P receptor 1 signaling regulates receptor activator of NF-kappaB ligand (RANKL) expression in rheumatoid arthritis Biochem Biophys Res Commun 419 2012 154 159
164. M. Nagai, D.B. Re, T. Nagata, A. Chalazonitis, T.M. Jessell, and H. Wichterle Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons Nat Neurosci 10 2007 615 622 (Pubitemid 46652435)
165. P. Gergely, B. Nuesslein-Hildesheim, D. Guerini, V. Brinkmann, M. Traebert, and C. Bruns The selective S1P receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate: translation from preclinical to clinical studies Br J Pharmacol 167 2012 1035 1047
166. T. Ohno, C. Hasegawa, S. Nakade, J. Kitagawa, N. Honda, and M. Ogawa The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling Biopharm Drug Dispos 31 2010 396 406
167. L. Piali, S. Froidevaux, P. Hess, O. Nayler, M.H. Bolli, and E. Schlosser The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation J Pharmacol Exp Ther 337 2011 547 556
168. J.B. Moberly, D.M. Ford, H. Zahir, S. Chen, T. Mochizuki, and K.E. Truitt Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients J Neuroimmunol 246 2012 100 107
169. Actelion Ponesimod [website] http://www1.actelion.com/en/scientists/ development-pipeline/phase-2/ponesimod.page 2012
170. Novartis Positive phase IIb data for BAF312 (siponimod) http://www.novartis.com/newsroom/media-releases/en/2012/1604172.shtml 2012
171. Vollmer TL, Selmaj K, Bar-Or A, Zipp F. A double-blind, placebo-controlled, phase 2, 26-week DreaMS trial of selective S1P recptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis. Presented at the 64th Annual Meeting of the American Academy of Neurology New Orleans 201; 2013.
172. J.P. Antel, and V.E. Miron Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies Clin Neurol Neurosurg 110 2008 951 957
173. C. Gasperini, and S. Ruggieri Emerging oral drugs for relapsing-remitting multiple sclerosis Expert Opin Emerg Drugs 16 2011 697 712
174. R. Gold, and J.S. Wolinsky Pathophysiology of multiple sclerosis and the place of teriflunomide Acta Neurol Scand 124 2011 75 84
175. T. Korn, T. Magnus, K. Toyka, and S. Jung Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - mechanisms independent of pyrimidine depletion J Leukoc Biol 76 2004 950 960 (Pubitemid 39458707)
176. J.E. Merrill, S. Hanak, S.F. Pu, J. Liang, C. Dang, and D. Iglesias-Bregna Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis J Neurol 256 2009 89 103
177. C. Wegner, C. Stadelmann, R. Pfortner, E. Raymond, S. Feigelson, and R. Alon Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis J Neuroimmunol 227 2010 133 143
178. W. Bruck, and C. Wegner Insight into the mechanism of laquinimod action J Neurol Sci 306 2011 173 179
179. J. Thone, G. Ellrichmann, S. Seubert, I. Peruga, D.H. Lee, and R. Conrad Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor Am J Pathol 180 2012 267 274
180. R.A. Linker, D.H. Lee, S. Ryan, A.M. van Dam, R. Conrad, and P. Bista Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway Brain 134 2011 678 692
181. R.H. Scannevin, S. Chollate, M.Y. Jung, M. Shackett, H. Patel, and P. Bista Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway J Pharmacol Exp Ther 341 2012 274 284
182. R. Aharoni, R. Saada, R. Eilam, L. Hayardeny, M. Sela, and R. Arnon Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis J Neuroimmunol 251 2012 14 24
183. Ruffini F, Rossi S, Bergamaschi A, Brambilla E, Finardi A, Motta C, et al. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult Scler in press. http://dx.doi.org/10.1177/1352458512469698.
184. W. Bruck, R. Pfortner, T. Pham, J. Zhang, L. Hayardeny, and V. Piryatinsky Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination Acta Neuropathol 124 2012 411 424
185. H. Wilms, J. Sievers, U. Rickert, M. Rostami-Yazdi, U. Mrowietz, and R. Lucius Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation J Neuroinflammation 7 2010 30
186. J. Zhao, A.N. Moore, J.B. Redell, and P.K. Dash Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury J Neurosci 27 2007 10240 10248 (Pubitemid 47450456)
187. A.F. Hubbs, S.A. Benkovic, D.B. Miller, J.P. O'Callaghan, L. Battelli, and D. Schwegler-Berry Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2 Am J Pathol 170 2007 2068 2076 (Pubitemid 47339279)
188. R. Nicholas, P. Giannetti, A. Alsanousi, T. Friede, and P.A. Muraro Development of oral immunomodulatory agents in the management of multiple sclerosis Drug Des Devel Ther 5 2011 255 274
189. R.A. Linker, D.H. Lee, M. Stangel, and R. Gold Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies Expert Rev Neurother 8 2008 1683 1690